Table 3.
Key HSV-1-Negative and -Positive Results (Median and IQR)
| BioFire HSV− (n = 524) | PCR HSV− (n = 287) | P | BioFire HSV+ (n = 13) | PCR HSV+ (n = 2) | ||||
|---|---|---|---|---|---|---|---|---|
| ≤18 y (n = 125) | >18 y (n = 399) | ≤18 y (n = 115) | >18 y (n = 172) | ≤18 y | >18 y | All Ages | All Ages | |
| Duration of hospitalization | 5 (9.5) | 9 (14)* | 5 (13) | 16 (20)* | .205 | <.001 | 25 (41) | 15; 27 |
| HSV testing | ||||||||
| LP to HSV results | 0.07 (0.14)* | 0.16 (0.16)* | 2.93 (2.82)* | 3.19 (2.56)* | <.001 | <.001 | 0.18 (0.18) | 20.14; 3.80 |
| Acyclovir administration to HSV results | 0.25 (0.60)* | 0.42 (1.08)* | 3.20 (3.52)* | 3.34 (3.55)* | <.001 | <.001 | 0.22 (0.32) | 19.96; 3.80 |
| Acyclovir administration to LP | 0.11 (0.33)* | 0.19 (1.06)* | 0.01 (0.60)* | 0.01 (0.90)* | <.001 | <.001 | 0.04 (0.12) | −0.18; 0 |
| Acyclovir treatment | ||||||||
| Duration of acyclovir | 0.27 (1.07)* | 1.04 (3.23)* | 2.48 (2.66)* | 2.67 (3.93)* | <.001 | <.001 | 12.56 (13.06) | 15.04; 0.64 |
| Admission to acyclovir administration | 0.80 (0.67)* | 0.93 (1.14)* | 1.06 (1.09)* | 1.43 (1.93)* | <.001 | <.001 | 2.43 (1.04) | 0.5; 7.76 |
| LP to acyclovir discontinuation | 0.10 (0.62)* | 0.57 (1.88)* | 2.47 (2.05)* | 2.78 (3.83)* | <.001 | <.001 | 12.53 (12.95) | 15.22; 0.64 |
| HSV result to acyclovir discontinuation | 0.02 (0.41) | 0.26 (1.81)* | 0.04 (2.24) | –0.25 (2.77)* | .154 | <.001 | 12.34 (12.77) | −4.92; −3.15 |
| Abnormal creatinine | ||||||||
| No. with abnormal creatinine at admission (%) | 2 (1.6) | 126 (31.6) | 3 (2.6) | 57 (33.1) | – | – | 1 (7.6) | 0 (0) |
| No. with abnormal creatinine after acyclovir (%) | 3 (2.4) | 157 (39.3) | 8 (7.0) | 74 (43.0) | – | – | 5 (38.5) | 1 (50.0) |
| No. with newly abnormal creatinine after acyclovir administration (%) | 1 (0.8)* | 49 (12.3) | 7 (6.1)* | 29 (16.9) | .021 | .163 | 4 (30.8) | 1 (50) |
| Admission to highest creatinine | 3.35 (4.40) | 5.04 (11.77) | 5.25 (39.96) | 6.71 (12.38) | .776 | .197 | 13.42 (11.90) | 15.49; – |
| Acyclovir administration to highest creatinine | 1.68 (1.46)* | 2.82 (7.29) | 3.93 (13.12)* | 2.74 (6.74) | .012 | .380 | 10.03 (8.62) | 14.99; – |
All values presented except for “No. with abnormal creatinine” are median (IQR), with the unit days. All BioFire+ results except for “No. with abnormal creatinine” are median (IQR), with the unit days. For standalone PCR+ results, the actual values for each case are presented.
Abbreviations: HSV, herpes simplex virus; IQR, interquartile range; LP, lumbar puncture; PCR, polymerase chain reaction.
*
Signifies statistical significance at α = .05.